It is known that the lack of comprehensive therapeutic effects of anti-glioma drugs is mediated in part by O6-methylguanine-DNA methyltransferase (MGMT)-mediated drug resistance (Lang et al., 2021). This evidence concerns the gene MGMT and glioma.